Lakewood, Colorado, April 17, 2013 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.14 per share of common stock. The dividend will be payable on June 14, 2013, to shareholders of record on May 27, 2013.

About Mesa Laboratories, Inc.

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into two divisions across four physical locations. Our Instruments division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries. Our Biological Indicators division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries

Forward Looking Statements

This press release may contain information that constitutes “forward-looking statements.” Generally, the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2012, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.

Contact

John J. Sullivan, Ph.D.; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000

Lakewood, Colorado, March 28th 2013

Mesa Labs, a Colorado-based process monitoring and validation solutions provider, has received 510(k) notification from the Food and Drug Administration for their new Smart-Well 1710 Biological Indicator Incubator.

Mesa Labs is pleased to announce that it has received 510(k) notification for its new 1710 Smart-Well^® Incubator–part of the Smart-Read^® Biological Indicator Monitoring System. The 1710 Smart-Well^® is an advancement of Mesa’s earlier edition Smart-Well incubator (Model 1701) which is a true biological system that provides fast biological results, automatic documentation and easy, one-step evaluation.

The 1710 model offers these enhanced features:

• Dual Integrated Digital Thermometers
• Improved Processor and Storage
• Larger, Color LCD Interface
• Password Protection
• Temperature Progress Meter

The Smart-Well^® Biological Indicator Monitoring system uses a real biological indicator (BI) — with no added enzyme or chemical integrator — which is incubated, evaluated, and documented in one simple, automated operation. Relying only upon bacterial spore growth, the Smart-Read^® system can detect sterilization failure in as few as three to five hours, and negative results can be confirmed with an additional five hours of incubation.

The Smart-Read^® system includes the Smart-Read^® EZTest self-contained biological indicator which is specially designed for rapid evaluation in Mesa’s advanced Smart-Well^® incubator.

Mesa Laboratories, Inc. (MLAB on the NASDAQ) offers biological indicators through its Bozeman, MT and  Omaha,NE manufacturing facilities.  Mesa also manufactures dialysis meters, gas flow meters, data loggers and torque testers.

To learn more, visit www.mesalabs.com

Lakewood, Colorado, February 6, 2013 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.14 per share of common stock. The dividend will be payable on March 15, 2013, to shareholders of record on February 27, 2013.

About Mesa Laboratories, Inc.

We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into two divisions across four physical locations. Our Instruments division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, semiconductor and petrochemical industries. Our Biological Indicators division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. (more…)

Lakewood, Colorado, February 5, 2013 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported an 18 percent increase in revenues for the third quarter ended December 31, 2012.

Highlights:
• Revenues for the third quarter increased 18 percent to $11,361,000 as compared to the same quarter last year
• Revenues for the nine months ended December 31, 2012 increased 17 percent to $33,627,000 as compared to the same period last year
• Net income for the nine months ended December 31, 2012 increased three percent to $5,891,000 as compared to the same period last year
• Non-GAAP adjusted net income for the nine months ended December 31, 2012 increased 11 percent to $7,144,0001as compared to the same period last year

Revenues for the third quarter increased 18 percent to $11,361,000 as compared to $9,650,000 for the same quarter last year. Net income for the third quarter decreased 22 percent to $1,543,000 or $0.44 per diluted share of common stock as compared to $1,987,000 or $0.57 per diluted share of common stock for the same quarter last year. Net income for the third quarter was impacted by $526,000, before tax, of Chief Financial Officer transition costs, which are one-time in nature. (more…)

Lakewood, Colorado, November 8, 2012 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported a 21 percent increase in revenues and a nine percent increase in net income for the second quarter ended September 30, 2012.

Highlights:

• Revenues for the second quarter increased 21 percent to $11,706,000 as compared to the same quarter last year
• Net income for the second quarter increased nine percent to $2,248,000 as compared to the same period last year
• Non-GAAP adjusted net income for the second quarter increased 21 percent to $2,684,0001as compared to the same period last year

Revenues for the second quarter increased 21 percent to $11,706,000 as compared to $9,701,000 for the same quarter last year. Net income for the second quarter increased nine percent to $2,248,000 or $0.64 per diluted share of common stock as compared to $2,053,000 or $0.59 per diluted share of common stock for the same quarter last year.

Revenues for the six months ended September 30, 2012 increased 17 percent to $22,266,000 as compared to $18,998,000 for the same period last year. Net income for the six months ended September 30, 2012 increased 16 percent to $4,348,000 or $1.23 per diluted share of common stock as compared to $3,733,000 or $1.09 per diluted share of common stock for the same period last year. (more…)

Lakewood, Colorado, November 7, 2012 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that our Board of Directors has declared a regular quarterly dividend of $0.14 per share of common stock, up from $.13 per share last quarter. The dividend will be payable December 14, 2012, to shareholders of record on November 30, 2012.

Since going public in 1984, we have maintained strong cash positions and have continued to build our balance sheet through steady earnings growth. The increase in the regular quarterly dividend rate from $0.13 to $0.14 per common share represents an eight percent increase from the previous dividend rate, and a 180 percent increase since initiation of the quarterly dividend policy in December 2003. (more…)

Lakewood, Colorado, October 11, 2012 – Mesa Laboratories, Inc. (NASDAQ:MLAB) reported today that Steven W. Peterson, Vice President and Chief Financial Officer of Mesa Laboratories, Inc., notified the Company of his intention to retire effective as of the close of business on November 30, 2012.  In connection with Mr. Peterson’s pending retirement, on October 29, 2012, John V. Sakys will join the Company as an Executive Vice President.  Immediately after Mr. Peterson’s retirement, the Board of Directors of the Company intends to appoint Mr. Sakys as the Company’s Chief Financial Officer.

John J. Sullivan, President and Chief Executive Officer, said, “Steve has been withMesasince 1985, and in the CFO position since 1990.  He has been instrumental in helpingMesagrow from its infancy to the global, highly profitable, diversified manufacturer that it is today. Mesaowes a debt of gratitude to Steve for his hard work and dedication throughout these past 27 years, and we all wish him well in his future endeavors.”

Mr. Sakys, 44, was most recently with The Berry Company, LLC, the fifth largest telephone directory publisher and search provider in theU.S.  Mr. Sakys held several positions with The Berry Company, and its predecessor company, Local Insight Regatta Holdings, Inc., most recently as its Vice President and Chief Accounting Officer.  In this capacity, Mr. Sakys was responsible for general accounting, SEC reporting, treasury, and tax compliance.  Prior to The Berry Company, from 2001 to 2009, Mr. Sakys was the Vice President and Chief Financial Officer of Isonics Corporation, a NASDAQ listed manufacturing company based in theDenverarea.

“We are excited to have a financial professional with John’s credentials and experience join theMesateam”, continued John J. Sullivan.  “While at Isonics, John gained extensive experience as the CFO of a multi-site manufacturing company.  He was involved in all aspects of financial reporting, investor relations, debt and equity raises, accounting, and operations management across three locations.  More recently, John’s experience at The Berry Company, including the management of its large accounting staff, has solidified his experience as a member of the executive team at a larger public company.  We look forward to John’s guidance as we execute our growth plans in the years ahead.” (more…)

LAKEWOOD, Colo., Aug. 9, 2012 /PRNewswire/ — Mesa Laboratories, Inc. (MLAB) (the “Company”) today reported a 14% increase in revenue and a 25% increase in net income for the first quarter of fiscal 2013, ended June 30, 2012.

Highlights:

• First quarter revenues increased 14% compared to the same period last fiscal year

• First quarter net income increased 25% to $2,099,000 compared to the same period last fiscal year

• First quarter non-GAAP adjusted net income increased 29% to $2,482,0001

• We acquired specific assets and certain liabilities of Bios International Corporation

For the first quarter of fiscal 2013, net revenues increased 14% to $10,559,000 from $9,297,000 in the same quarter last year. GAAP net income for the quarter increased 25% to $2,099,000 or $0.59 per diluted share compared to $1,679,000 or $0.49 per diluted share one year ago.

On a non-GAAP basis (which excludes acquisition related intangible amortization, net of tax effects), adjusted net income for the first quarter ended June 30, 2012 increased 29% to $2,482,000 or $0.70 per diluted share of common stock compared to $1,918,000 or $0.56 per diluted share of common stock last year. (more…)

Mesa Laboratories, a Lakewood, CO based manufacturer of electronic instruments and disposables, is announcing that it has developed a new, updated logo to coordinate with the release of its redesigned website and to increase the recognition of the Mesa name. The redesign incorporated aspects of the former logo while allowing the company to utilize the new logo for more web 2.0 applications and improve its visual impact.

During the last several years Mesa Laboratories has grown significantly in revenue and product line depth. As a result Mesa now has a much broader product line portfolio, significantly larger distribution channel, an enhanced valuation and a presence in several additional industries.

With these expanded business capabilities it became clear that the time had come to refresh Mesa’s image in the marketplace. The current logo is a much older design and not in line with Mesa’s improved product offering and trajectory for planned growth. (more…)

LAKEWOOD, Colo., May 15, 2012 /PRNewswire/ — Mesa Laboratories, Inc. (MLAB), a Lakewood, Colorado based manufacturer of electronic instruments and disposables, today announced the acquisition of the flow calibrator business of Bios International Corporation, a New Jersey company.

Under the terms of the transaction, Mesa Labs has acquired essentially all of the assets of Bios’ business involving the design, manufacturing, sales and service of gas flow calibration instrumentation. The flow calibrator business was acquired by Mesa for an initial payment of $16.66 million in cash, plus a possible future payment of up to $6.71 million in cash, dependant on the growth rate of the business during the first three years following the acquisition. In the 12-month period ended April 30, 2012, the flow calibrator business of Bios had unaudited revenues of approximately $6.7 million. Due to excellent profit margins and a favorable tax treatment of this asset deal, the addition of the flow calibrator business is expected to increase Mesa’s cash flow significantly and be accretive to Mesa’s GAAP earnings per share beginning in the current fiscal year, ending March 31, 2013. (more…)